6‐Month abstinence ‐ homozygous minor · people who smoke
It is very uncertain whether active NRT changes 6‐Month abstinence ‐ homozygous minor compared with placebo ‐ DRD4 (exon 3 48 bp) ‐ non‐Hispanic white (very low certainty).
1 finding from 1 review
End of treatment · people who smoke
Active NRT showed no clear difference in end of treatment compared with placebo ‐ DRD4 (exon 3 48 bp) ‐ non‐Hispanic white (low certainty).
1 finding from 1 review
Abstinence at end of treatment ‐ heterozygous · people who smoke
Active NRT probably leads to higher abstinence at end of treatment ‐ heterozygous compared with placebo ‐ rs1051730 ‐ non‐Hispanic white (moderate certainty).
1 finding from 1 review
End of treatment ‐ homozygous major · people who smoke
It is very uncertain whether active NRT changes end of treatment ‐ homozygous major compared with placebo ‐ DRD4 (exon 3 48 bp) ‐ non‐Hispanic white (very low certainty).
1 finding from 1 review
End of treatment ‐ heterozygous · people who smoke
It is very uncertain whether active NRT changes end of treatment ‐ heterozygous compared with placebo ‐ DRD4 (exon 3 48 bp) ‐ non‐Hispanic white (very low certainty).
1 finding from 1 review
End of treatment ‐ homozygous minor · people who smoke
Active NRT showed no clear difference in end of treatment ‐ homozygous minor compared with placebo ‐ DRD4 (exon 3 48 bp) ‐ non‐Hispanic white (low certainty).
1 finding from 1 review
Abstinence · people who smoke
Active NRT probably leads to higher 6‐Month abstinence compared with placebo ‐ NMR ‐ non‐Hispanic black and white (moderate certainty).
1 finding from 1 review
6‐Month abstinence ‐ slow NMR · people who smoke
Active NRT probably leads to higher 6‐Month abstinence ‐ slow NMR compared with placebo ‐ NMR ‐ non‐Hispanic black and white (moderate certainty).
1 finding from 1 review
6‐Month abstinence ‐ normal NMR · people who smoke
Active NRT showed no clear difference in 6‐Month abstinence ‐ normal NMR compared with placebo ‐ NMR ‐ non‐Hispanic black and white (low certainty).
1 finding from 1 review
End of treatment · people who smoke
Active NRT probably leads to higher end of treatment compared with placebo ‐ NMR ‐ non‐Hispanic black and white (moderate certainty).
1 finding from 1 review
End of treatment ‐ slow NMR · people who smoke
Active NRT probably leads to higher end of treatment ‐ slow NMR compared with placebo ‐ NMR ‐ non‐Hispanic black and white (moderate certainty).
1 finding from 1 review
End of treatment ‐ normal NMR · people who smoke
Active NRT showed no clear difference in end of treatment ‐ normal NMR compared with placebo ‐ NMR ‐ non‐Hispanic black and white (low certainty).
1 finding from 1 review
Abstinence at end of treatment ‐ homozygous minor · people who smoke
Active NRT may leads to higher abstinence at end of treatment ‐ homozygous minor compared with placebo ‐ rs1051730 ‐ non‐Hispanic white (low certainty).
1 finding from 1 review
End of treatment · people who smoke
Active NRT showed no clear difference in end of treatment compared with placebo ‐ rs16969968 ‐ non‐Hispanic white (moderate certainty).
1 finding from 1 review
End of treatment ‐ homozygous major · people who smoke
Active NRT showed no clear difference in end of treatment ‐ homozygous major compared with placebo ‐ rs16969968 ‐ non‐Hispanic white (low certainty).
1 finding from 1 review
End of treatment ‐ heterozygous · people who smoke
Active NRT leads to higher end of treatment ‐ heterozygous compared with placebo ‐ rs16969968 ‐ non‐Hispanic white (high certainty).
1 finding from 1 review
End of treatment ‐ homozygous minor · people who smoke
Active NRT showed no clear difference in end of treatment ‐ homozygous minor compared with placebo ‐ rs16969968 ‐ non‐Hispanic white (low certainty).
1 finding from 1 review